Depicting the underlying mechanisms of emricasan in advanced chronic liver disease
The study characterizes the effects, and underlying mechanisms, of the pan-caspase inhibitor emricasan on portal hypertension, fibrosis and liver cells phenotype in pre-clinical models of advanced cirrhosis.